Literature DB >> 35288509

Evidence for spontaneous cannabinoid withdrawal in mice.

Carol Paronis1,2,3, Christos Iliopoulos-Tsoutsouvas3, Ioannis Papanastasiou3, Alex Makriyannis2,3, Jack Bergman1, Spyros P Nikas3.   

Abstract

Although the behavioral effects of acute and chronic exposure to cannabinoids have been extensively studied in mice, spontaneous withdrawal following exposure to cannabinoids has not been well characterized in this species. To address this issue, different groups of mice were treated for 5 days with saline, 20-36 mg/kg/day of the CB partial agonist Δ9-tetrahydrocannabinol (Δ9-THC), or 0.06-0.1 mg/kg/day of the CB high-efficacy agonist AM2389. Initial studies assessed changes in observable behavior (paw tremors) that were scored from the recordings taken at 4 or 24 h after the last injection. Subsequently, radiotelemetry was used to continuously measure body temperature and locomotor activity before (baseline), during, and after the 5-day dosing regimens. Results show that increases in paw tremors occurred following 5-day exposure to AM2389 or Δ9-THC. In telemetry studies, acute AM2389 or THC decreased both temperature and activity. Rapid tolerance occurred to the hypothermic effects of the cannabinoids, whereas locomotor activity continued to be suppressed following each drug injection. In contrast, increases in locomotor activity were evident 12-72 h after discontinuing daily injections of either 0.06 or 0.1 mg/kg/day AM2389. Increases in locomotor activity were also noted in mice treated daily with 30 or 36, but not 20 mg/kg/day Δ9-THC; these effects were smaller and appeared later than effects seen in AM2389-treated mice. These results indicate that the discontinuation of daily treatment with a CB high-efficacy agonist will yield evidence of spontaneous withdrawal that may reflect prior dependence, and that the degree of cannabinoid dependence may vary in relation to the dose or efficacy of the agonist injected daily.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35288509      PMCID: PMC8924453          DOI: 10.1097/FBP.0000000000000665

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  45 in total

1.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

2.  Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat.

Authors:  Eric Murillo-Rodriguez; Frank Désarnaud; Oscar Prospéro-García
Journal:  Life Sci       Date:  2006-01-23       Impact factor: 5.037

3.  Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single dose of methadone.

Authors:  C Wright; G E Bigelow; M L Stitzer; I A Liebson
Journal:  Drug Alcohol Depend       Date:  1991-03       Impact factor: 4.492

4.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

5.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

6.  Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.

Authors:  B R Martin; D R Compton; B F Thomas; W R Prescott; P J Little; R K Razdan; M R Johnson; L S Melvin; R Mechoulam; S J Ward
Journal:  Pharmacol Biochem Behav       Date:  1991-11       Impact factor: 3.533

7.  Comparison of behavioral effects of nicotine, d-amphetamine, caffeine and dimethylheptyl tetrahydrocannabinol in squirrel monkeys.

Authors:  T R Davis; C J Kensler; P B Dews
Journal:  Psychopharmacologia       Date:  1973-08-22

8.  Abstinence symptoms during withdrawal from chronic marijuana use.

Authors:  E M Kouri; H G Pope
Journal:  Exp Clin Psychopharmacol       Date:  2000-11       Impact factor: 3.157

9.  Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.

Authors:  Kristen R Trexler; Sara R Nass; Molly S Crowe; Joshua D Gross; Margaret S Jones; Austin W McKitrick; David P Siderovski; Steven G Kinsey
Journal:  Drug Alcohol Depend       Date:  2018-07-07       Impact factor: 4.492

10.  Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols.

Authors:  Spyros P Nikas; Rishi Sharma; Carol A Paronis; Shashank Kulkarni; Ganesh A Thakur; Dow Hurst; JodiAnne T Wood; Roger S Gifford; Girija Rajarshi; Yingpeng Liu; Jimit Girish Raghav; Jason Jianxin Guo; Torbjörn U C Järbe; Patricia H Reggio; Jack Bergman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2014-12-16       Impact factor: 7.446

View more
  2 in total

1.  Altered sleep during spontaneous cannabinoid withdrawal in male mice.

Authors:  Galen Missig; Niyati Mehta; James O Robbins; Cameron H Good; Christos Iliopoulos-Tsoutsouvas; Alex Makriyannis; Spyros P Nikas; Jack Bergman; William A Carlezon; Carol A Paronis
Journal:  Behav Pharmacol       Date:  2022-04-01       Impact factor: 2.293

2.  Effects of cannabinoid exposure on short-term memory and medial orbitofrontal cortex function and chemistry in adolescent female rhesus macaques.

Authors:  Stephen J Kohut; Lei Cao; Dionyssios Mintzopolous; Shan Jiang; Spyros P Nikas; Alexandros Makriyannis; Chun S Zou; J Eric Jensen; Blaise B Frederick; Jack Bergman; Brian D Kangas
Journal:  Front Neurosci       Date:  2022-09-30       Impact factor: 5.152

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.